{"id":"NCT02135419","sponsor":"AIDS Malignancy Consortium","briefTitle":"Treatment in Preventing Anal Cancer in Patients With HIV and Anal High-Grade Lesions","officialTitle":"ANCHOR Study: Anal Cancer/HSIL Outcomes Research Study","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-09-24","primaryCompletion":"2021-08-06","completion":"2024-03-31","firstPosted":"2014-05-12","resultsPosted":"2022-12-02","lastUpdate":"2024-07-26"},"enrollment":4446,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Anal Cancer","High-grade Squamous Intraepithelial Lesion","HIV Infection","Human Papilloma Virus Infection"],"interventions":[{"type":"DRUG","name":"imiquimod","otherNames":["Aldara","IMQ","R 837"]},{"type":"DRUG","name":"fluorouracil","otherNames":["5-fluorouracil","5-Fluracil","5-FU","Efudex"]},{"type":"DEVICE","name":"infrared photocoagulation therapy","otherNames":["infrared coagulation","IRC"]},{"type":"DEVICE","name":"thermal ablation therapy","otherNames":[]},{"type":"DEVICE","name":"laser therapy","otherNames":["therapy, laser"]},{"type":"OTHER","name":"clinical observation","otherNames":["observation"]},{"type":"OTHER","name":"laboratory biomarker analysis","otherNames":[]}],"arms":[{"label":"Arm I (treatment)","type":"EXPERIMENTAL"},{"label":"Arm II (active monitoring) (closed since SEP2021)","type":"ACTIVE_COMPARATOR"}],"summary":"The randomized phase of the trial compared topical or ablative treatment with active monitoring in preventing anal cancer in patients with human immunodeficiency virus (HIV) and high-grade squamous intraepithelial lesions (HSIL). Anal HSIL is tissue in the anal canal that has been damaged by infection with human papillomavirus (HPV) and is at risk for turning into anal cancer.\n\nThe ANCHOR Data Safety Monitoring Board (DSMB) determined that the primary study endpoint was completed, based on the data and statistical analysis presented to them on 07SEP2021.\n\nIn the post-randomization phase of this trial, all enrolled participants are offered treatment for HSIL and/or follow-up, at the participant's choice.","primaryOutcome":{"measure":"Anal Cancer Incidence","timeFrame":"Time from randomization to diagnosis of anal cancer, assessed up to 5 years post randomization","effectByArm":[{"arm":"Arm I (Treatment)","deltaMin":173,"sd":null},{"arm":"Arm II (Active Monitoring) (Closed Since SEP2021)","deltaMin":402,"sd":null}],"pValues":[]},"eligibility":{"minAge":"35 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":14,"exclusionCount":9},"locations":{"siteCount":25,"countries":["United States","Puerto Rico"]},"refs":{"pmids":["35017115","35704479","35416975","33594934"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":370,"n":2227},"commonTop":["Infections and Infestations, other","Anal pain","Hypertension","Anal hemorrhage","Neoplasms, other"]}}